Finding 1151532 (2024-104)

Significant Deficiency Repeat Finding
Requirement
L
Questioned Costs
-
Year
2024
Accepted
2025-08-28
Audit: 365222
Organization: Pancare of Florida, INC (FL)

AI Summary

  • Core Issue: The Organization lacks proper documentation for report reviews before submission, leading to repeated findings from previous years.
  • Impacted Requirements: Compliance with 2 CFR section 200.303, which mandates effective internal controls for managing federal awards.
  • Recommended Follow-Up: Implement a clear documentation process for report preparation and review, ensuring all approvals are recorded and considered for accuracy.

Finding Text

2024-104 Lack of Controls Related to Filing Reports (repeated, prior years 2023-104) (initially reported 2023) Assistance Listing Number: 93.224, 93.527 and 93.211 Name of Federal Agency: Department of Health and Human Services, HRSA Program Title: Health Center Program (Community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care) and Grants for New and Expanded Services Under the Health Center Program and Rural Telemedicine Grants Compliance Requirement: Reporting Pass-through Entity: N/A Federal Grant/Contract Number and Grant Year: H8006452 (2024 and 2023), H2E45500 (2022), H8K49674 (2023), COVID-19 H2E50094 (2023), H8N53812 (2024), C1650381 (2023), COVID-19 H8L50549 (2023), COVID-19 H8G48569 (2022).GA142923 (2021) G2846293 (2022) and G3949501 (2023) Finding Type: Significant Deficiency in Internal Control Questioned Costs: $0 Condition: The Organization did not maintain proper documentation to support the review of the report prior to submission to the grantor, other than the review done by the preparer. In four of the reports selected for testing under ALN 93.224 and 93.527 two reports did not have documentation of approval by the CEO prior to submission. In three of the reports selected for testing under ALN 93.211 two reports did not have documentation of approval by the CEO prior to submission. This is a systemic issue that has been a finding in the previous year. The sample was not statistically valid. Criteria: 2 CFR section 200.303 requires that nonfederal entities receiving federal awards establish and maintain internal control over the federal awards that provides reasonable assurance that the nonfederal entity is managing the federal awards in compliance with federal statutes, regulations, and the terms and conditions of the federal awards. Cause: The Organization did not have a process in place for review of the data being reported on the HRSA website for the funds being expensed under the federal award programs. Effect: The Organization could submit incorrect information. Recommendation: Documentation should be kept that clearly documents who prepared the information, who reviewed the information, and that the reviewer considered whether the information was complete and accurate. Views of Responsible Officials and Planned Corrective Actions: The Organization has hired a new Chief Financial Officer as well as additional supporting staff within the finance department. The accounting staff was restructured in November 2024 with the addition of a Finance Manager and Senior Accountant to strengthen internal controls and facilitate segregation of duties best practices for day-to-day activities. In addition to review of month-end journal entries, reporting requirements with additional review was also implemented in 2025.

Categories

Internal Control / Segregation of Duties Subrecipient Monitoring HUD Housing Programs Reporting Significant Deficiency Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 575077 2024-101
    Material Weakness Repeat
  • 575078 2024-104
    Significant Deficiency Repeat
  • 575079 2024-105
    Material Weakness Repeat
  • 575080 2024-106
    Material Weakness
  • 575081 2024-101
    Material Weakness Repeat
  • 575082 2024-104
    Significant Deficiency Repeat
  • 575083 2024-105
    Material Weakness Repeat
  • 575084 2024-106
    Material Weakness
  • 575085 2024-101
    Material Weakness Repeat
  • 575086 2024-104
    Significant Deficiency Repeat
  • 575087 2024-105
    Material Weakness Repeat
  • 575088 2024-106
    Material Weakness
  • 575089 2024-101
    Material Weakness Repeat
  • 575090 2024-104
    Significant Deficiency Repeat
  • 575091 2024-105
    Material Weakness Repeat
  • 575092 2024-106
    Material Weakness
  • 575093 2024-101
    Material Weakness Repeat
  • 575094 2024-104
    Significant Deficiency Repeat
  • 575095 2024-105
    Material Weakness Repeat
  • 575096 2024-106
    Material Weakness
  • 575097 2024-104
    Significant Deficiency Repeat
  • 575098 2024-101
    Material Weakness Repeat
  • 575099 2024-104
    Significant Deficiency Repeat
  • 575100 2024-105
    Material Weakness Repeat
  • 575101 2024-106
    Material Weakness
  • 575102 2024-101
    Material Weakness Repeat
  • 575103 2024-104
    Significant Deficiency Repeat
  • 575104 2024-105
    Material Weakness Repeat
  • 575105 2024-106
    Material Weakness
  • 575106 2024-101
    Material Weakness Repeat
  • 575107 2024-104
    Significant Deficiency Repeat
  • 575108 2024-105
    Material Weakness Repeat
  • 575109 2024-106
    Material Weakness
  • 575110 2024-102
    Significant Deficiency
  • 575111 2024-104
    Significant Deficiency Repeat
  • 575112 2024-105
    Material Weakness Repeat
  • 575113 2024-106
    Material Weakness
  • 575114 2024-107
    Significant Deficiency
  • 575115 2024-102
    Significant Deficiency
  • 575116 2024-104
    Significant Deficiency Repeat
  • 575117 2024-105
    Material Weakness Repeat
  • 575118 2024-106
    Material Weakness
  • 575119 2024-107
    Significant Deficiency
  • 575120 2024-104
    Significant Deficiency Repeat
  • 575121 2024-105
    Material Weakness Repeat
  • 575122 2024-106
    Material Weakness
  • 575123 2024-107
    Significant Deficiency
  • 1151519 2024-101
    Material Weakness Repeat
  • 1151520 2024-104
    Significant Deficiency Repeat
  • 1151521 2024-105
    Material Weakness Repeat
  • 1151522 2024-106
    Material Weakness
  • 1151523 2024-101
    Material Weakness Repeat
  • 1151524 2024-104
    Significant Deficiency Repeat
  • 1151525 2024-105
    Material Weakness Repeat
  • 1151526 2024-106
    Material Weakness
  • 1151527 2024-101
    Material Weakness Repeat
  • 1151528 2024-104
    Significant Deficiency Repeat
  • 1151529 2024-105
    Material Weakness Repeat
  • 1151530 2024-106
    Material Weakness
  • 1151531 2024-101
    Material Weakness Repeat
  • 1151533 2024-105
    Material Weakness Repeat
  • 1151534 2024-106
    Material Weakness
  • 1151535 2024-101
    Material Weakness Repeat
  • 1151536 2024-104
    Significant Deficiency Repeat
  • 1151537 2024-105
    Material Weakness Repeat
  • 1151538 2024-106
    Material Weakness
  • 1151539 2024-104
    Significant Deficiency Repeat
  • 1151540 2024-101
    Material Weakness Repeat
  • 1151541 2024-104
    Significant Deficiency Repeat
  • 1151542 2024-105
    Material Weakness Repeat
  • 1151543 2024-106
    Material Weakness
  • 1151544 2024-101
    Material Weakness Repeat
  • 1151545 2024-104
    Significant Deficiency Repeat
  • 1151546 2024-105
    Material Weakness Repeat
  • 1151547 2024-106
    Material Weakness
  • 1151548 2024-101
    Material Weakness Repeat
  • 1151549 2024-104
    Significant Deficiency Repeat
  • 1151550 2024-105
    Material Weakness Repeat
  • 1151551 2024-106
    Material Weakness
  • 1151552 2024-102
    Significant Deficiency
  • 1151553 2024-104
    Significant Deficiency Repeat
  • 1151554 2024-105
    Material Weakness Repeat
  • 1151555 2024-106
    Material Weakness
  • 1151556 2024-107
    Significant Deficiency
  • 1151557 2024-102
    Significant Deficiency
  • 1151558 2024-104
    Significant Deficiency Repeat
  • 1151559 2024-105
    Material Weakness Repeat
  • 1151560 2024-106
    Material Weakness
  • 1151561 2024-107
    Significant Deficiency
  • 1151562 2024-104
    Significant Deficiency Repeat
  • 1151563 2024-105
    Material Weakness Repeat
  • 1151564 2024-106
    Material Weakness
  • 1151565 2024-107
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.526 Covid-19 Grants for Capital Development in Health Centers $728,277
10.766 Community Facilities Loans and Grants $411,641
93.224 Covid-19 Health Center Program (community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care) $346,967
93.211 Telehealth Programs $309,134
93.918 Grants to Provide Outpatient Early Intervention Services with Respect to Hiv Disease $275,916
93.224 Health Center Program (community Health Centers, Migrant Health Centers, Health Care for the Homeless, and Public Housing Primary Care) $175,931
93.939 Hiv Prevention Activities Non-Governmental Organization Based $149,480
93.527 Grants for New and Expanded Services Under the Health Center Program $121,766
93.243 Substance Abuse and Mental Health Services Projects of Regional and National Significance $103,014
10.855 Distance Learning and Telemedicine Loans and Grants $59,029
93.969 Pphf Geriatric Education Centers $33,933
93.527 Covid-19 Grants for New and Expanded Services Under the Health Center Program $27,500